Mads Brix Kronborg

Risk of cardiac implantable electronic device malfunctioning during pencil beam proton scanning in an in vitro setting

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Risk of cardiac implantable electronic device malfunctioning during pencil beam proton scanning in an in vitro setting. / Bjerre, Henrik Laurits; Kronborg, Mads Brix; Nielsen, Jens Cosedis et al.
In: International Journal of Radiation Oncology, Biology, Physics, Vol. 111, No. 1, 09.2021, p. 186-195.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Bjerre HL, Kronborg MB, Nielsen JC, Høyer M, Jensen MF, Zaremba T et al. Risk of cardiac implantable electronic device malfunctioning during pencil beam proton scanning in an in vitro setting. International Journal of Radiation Oncology, Biology, Physics. 2021 Sept;111(1):186-195. Epub 2021 Apr 9. doi: 10.1016/j.ijrobp.2021.03.053

Author

Bibtex

@article{0d6069fbe119425db6c3f49a7bc48f2a,
title = "Risk of cardiac implantable electronic device malfunctioning during pencil beam proton scanning in an in vitro setting",
abstract = "PURPOSE: Cardiac implantable electronic devices (CIED) are sensitive to scattered secondary neutrons from proton beam irradiation. This experimental in vitro study investigated risk of CIED errors during pencil beam proton therapy.METHODS AND MATERIAL: We used 62 explanted CIEDs from four manufacturers; 49 CIEDs were subjected to a simulated clinical protocol with daily 2 Gy relative biological effectiveness (RBE) fractions prescribed to the phantom. Devices were located at three different lateral distances from the spread-out Bragg peak to investigate risk of permanent or temporary device errors. Additionally, 13 devices with leads connected, were monitored live during consecutive irradiations to investigate risk of noise, over- or under-sense, pace-inhibition and inappropriate shock-therapy.RESULTS: We detected 61 reset errors in 1,728 fractions and all except one CIED were reprogrammed to normal function. All, except one reset, occurred in devices from the same manufacturer. These were successfully reprogrammed to normal function. The one remaining CIED was locked in permanent safety mode. Secondary neutron dose, as estimated by Monte Carlo simulations, was found to significantly increase the odds of CIED resets by 55% per mSv. Clinically significant battery depletion was observed in five devices. We observed no noise, over- or under-sense, pace-inhibition or inappropriate shock therapy during 362 fractions of live-monitoring.CONCLUSION: Reprogrammable CIED reset was the most commonly observed malfunction during proton therapy and reset risk depended on secondary neutron exposure. The benefits of proton therapy are expected to outweigh the risk of CIED malfunctioning for most patients.",
author = "Bjerre, {Henrik Laurits} and Kronborg, {Mads Brix} and Nielsen, {Jens Cosedis} and Morten H{\o}yer and Jensen, {Maria Fuglsang} and Tomas Zaremba and L{\ae}gdsmand, {Peter Magnus Trock} and S{\o}ndergaard, {Christian Skou} and H{\aa}kan Nystr{\"o}m and Kronborg, {Camilla Jensenius Skovhus}",
note = "Copyright {\textcopyright} 2021. Published by Elsevier Inc.",
year = "2021",
month = sep,
doi = "10.1016/j.ijrobp.2021.03.053",
language = "English",
volume = "111",
pages = "186--195",
journal = "International Journal of Radiation Oncology, Biology, Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Risk of cardiac implantable electronic device malfunctioning during pencil beam proton scanning in an in vitro setting

AU - Bjerre, Henrik Laurits

AU - Kronborg, Mads Brix

AU - Nielsen, Jens Cosedis

AU - Høyer, Morten

AU - Jensen, Maria Fuglsang

AU - Zaremba, Tomas

AU - Lægdsmand, Peter Magnus Trock

AU - Søndergaard, Christian Skou

AU - Nyström, Håkan

AU - Kronborg, Camilla Jensenius Skovhus

N1 - Copyright © 2021. Published by Elsevier Inc.

PY - 2021/9

Y1 - 2021/9

N2 - PURPOSE: Cardiac implantable electronic devices (CIED) are sensitive to scattered secondary neutrons from proton beam irradiation. This experimental in vitro study investigated risk of CIED errors during pencil beam proton therapy.METHODS AND MATERIAL: We used 62 explanted CIEDs from four manufacturers; 49 CIEDs were subjected to a simulated clinical protocol with daily 2 Gy relative biological effectiveness (RBE) fractions prescribed to the phantom. Devices were located at three different lateral distances from the spread-out Bragg peak to investigate risk of permanent or temporary device errors. Additionally, 13 devices with leads connected, were monitored live during consecutive irradiations to investigate risk of noise, over- or under-sense, pace-inhibition and inappropriate shock-therapy.RESULTS: We detected 61 reset errors in 1,728 fractions and all except one CIED were reprogrammed to normal function. All, except one reset, occurred in devices from the same manufacturer. These were successfully reprogrammed to normal function. The one remaining CIED was locked in permanent safety mode. Secondary neutron dose, as estimated by Monte Carlo simulations, was found to significantly increase the odds of CIED resets by 55% per mSv. Clinically significant battery depletion was observed in five devices. We observed no noise, over- or under-sense, pace-inhibition or inappropriate shock therapy during 362 fractions of live-monitoring.CONCLUSION: Reprogrammable CIED reset was the most commonly observed malfunction during proton therapy and reset risk depended on secondary neutron exposure. The benefits of proton therapy are expected to outweigh the risk of CIED malfunctioning for most patients.

AB - PURPOSE: Cardiac implantable electronic devices (CIED) are sensitive to scattered secondary neutrons from proton beam irradiation. This experimental in vitro study investigated risk of CIED errors during pencil beam proton therapy.METHODS AND MATERIAL: We used 62 explanted CIEDs from four manufacturers; 49 CIEDs were subjected to a simulated clinical protocol with daily 2 Gy relative biological effectiveness (RBE) fractions prescribed to the phantom. Devices were located at three different lateral distances from the spread-out Bragg peak to investigate risk of permanent or temporary device errors. Additionally, 13 devices with leads connected, were monitored live during consecutive irradiations to investigate risk of noise, over- or under-sense, pace-inhibition and inappropriate shock-therapy.RESULTS: We detected 61 reset errors in 1,728 fractions and all except one CIED were reprogrammed to normal function. All, except one reset, occurred in devices from the same manufacturer. These were successfully reprogrammed to normal function. The one remaining CIED was locked in permanent safety mode. Secondary neutron dose, as estimated by Monte Carlo simulations, was found to significantly increase the odds of CIED resets by 55% per mSv. Clinically significant battery depletion was observed in five devices. We observed no noise, over- or under-sense, pace-inhibition or inappropriate shock therapy during 362 fractions of live-monitoring.CONCLUSION: Reprogrammable CIED reset was the most commonly observed malfunction during proton therapy and reset risk depended on secondary neutron exposure. The benefits of proton therapy are expected to outweigh the risk of CIED malfunctioning for most patients.

UR - http://www.scopus.com/inward/record.url?scp=85106579733&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2021.03.053

DO - 10.1016/j.ijrobp.2021.03.053

M3 - Journal article

C2 - 33845147

VL - 111

SP - 186

EP - 195

JO - International Journal of Radiation Oncology, Biology, Physics

JF - International Journal of Radiation Oncology, Biology, Physics

SN - 0360-3016

IS - 1

ER -